Rifamide is a new semisynthetic derivative of the famnily of rifamycins, a group of antibiotics isolated by Sensi, Margalith, and Timbal in 1959 from the fermentation broths of S. mediterranei n. sp., which also includes rifamycin SV, fairly widely used in clinical practice.
Rifamide is the diethylamide of rifamycin B, one of the compounds which are found in the fermentation broths, and has the following structural formula:-The chemical and physico-chemical properties of this compound have been described by Maggi, Galo, and Sensi (1965) ; it is an orange-yellow crystalline powder of which the sodium salt is soluble in water (1P5 g./10 ml.).
Toxicological studies were carried out in labpratory animals by Dezulian, Serralunga, and Maffi (1966) . The LD.0 of rifamide administered subcutaneously has been shown to be of the order of 640 mg./kg. in mice, 2,500 mg./kg. in rats and
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CH3 H Study of the excretion in bile and concentration in the gall bladder wall of rifamide rabbits, and 425 mg./kg. in dogs. The intravenous LD5o values in these animals were found to be of the order of 315 to 550 mg./kg. In chronic toxicity tests, dogs treated intravenously with 50mg./kg. of rifamide twice daily for six months did not show any sign of disease due to the compound (Dezulian et al., 1966) .
Rifamide shows antimicrobial activity mainly against Gram-positive organisms. In vitro, minimal inhibitory concentrations have been shown to be of the order of 0-01 to 0-02 p,g./ml. for Staphylococcus aureus, 005 to 0 1 ,ug./ml. for Streptococcus, and 0-02 ,ug./ml. for Diplococcus pneumoniae.
As far as Gram-negative micro-organisms are concerned, minimal inhibitory concentrations have been found to be of the order of 20 ,ug./ml. for E. coli, Aerobacter aerogenes, Proteus vulgaris and morganii, Salmonella typhi, and Shigella dysenteriae.
Further data on antimicrobial activity of rifamide are reported in the papers by Pallanza, Furdsz, Timbal, and Carniti (1965) , and Fiiresz, Arioli, and Scotti (1965) .
Distribution studies carried out in animals have
shown that rifamide, like other members of the rifamycin family, is excreted in high degree in the bile (Maffii and Schiatti, 1966) . In rats given 5 to 10 and 25 mg./kg. intravenously, from 56 to 84 % of the dose was recovered in the bile produced within two hours after administration. On the basis of low toxicity, good antimicrobial activity, and high biliary excretion of rifamide, this study was undertaken in order to establish whether the antibiotic could be used therapeutically in man in infections of the biliary tree. We also intended to evaluate the possible effects of the treatment on certain components of human bile.
A series of experiments has therefore been carried out in man in order to evaluate the biliary excretion of rifamide after repeated intramuscular administration; the possible effects of the treatment on the bile volume and on the biliary excretion of bilirubin and cholesterol; and the concentration of rifamide in the gall bladder wall.
MATERIAL AND METHODS
EXCRETION OF RIFAMIDE AND EFFECT ON SOME BILE VARIABLES This study was carried out in four subjects with biliary drainage (T tube) on the sixth to seventh days after cholecystectomy. Rifamide was administered intramuscularly at a dose of 150 mg. every eight hours. For each subject the experiment was divided into a treatment period and a control period of 24 hours each, in order to avoid spontaneous variations of certain parameters under study, e.g., bile volume in relation to meals or periods of sleep, which could affect the results. In two subjects (3 and 4) the observations were continued for a further period of 24 hours. The periods of treatment and control were assigned in different sequences, according to a cross-over design.
Bile was collected every hour, the volume measured, and each sample was assayed for the following components:
Rifamide The assays have been carried out by the agar plate method using Staphylococcus aureus ATCC 6538 as test organism . Rifamide concentration is expressed in ,ug./ml. The recovery, per hour and cumulative, has been calculated and expressed in milligrams.
Bilirubin Bile samples were diluted 1: 20 and analysed for bilirubin content by the method of Malloy and Evelyn (1937) . A preliminary study showed that, in these conditions, rifamide does not interfere in the diazo determination of bilirubin. The concentration of bilirubin in bile is expressed in terms of mg./100 ml. The excretion, per hour and cumulative, has been calculated.
Cholesterol The assays have been carried out by the method of Sperry and Webb (1950) after extraction of cholesterol carried out according to the method of Foldes (1943) . Cholesterol concentrations (mg./100 ml.) per hour and cumulative excretion (mg.) have been calculated.
The data on the volume of the bile drained and on the biliary concentration of bilirubin and cholesterol were analysed by means of an analysis of variance (Snedecor, 1961) . The experiments have been analysed as split-plots (Cochran and Cox, 1957) on the basis that once the period of observation was assigned (control or treatment), the observations corresponding to the different times could not occur in random order.
CONCENTRATION OF RIFAMIDE IN THE GALL BLADDER WALL
This study was carried out in 16 subjects who underwent operation for cholecystectomy. Rifamide was administered at the dose of 150 mg. every eight hours intramuscularly, during a period ranging from one day to eight days before the operation.
Gall bladders were collected and kept in sterile tubes. They were cut, washed with saline, weighed and crushed with quartz grains in a mortar. A homogenate, 1:10 w/v with saline, was prepared and after centrifugation a microbiological assay was carried out on the supematant using the method described for bile assay. The concentration of rifamide in the gall bladder has been expressed as tLg./g. of tissue and ug./organ. Figures 1 to 4 . Peak bile concentrations occurred, in general, at three to four hours after injection, ranging between 1,100 and 2,400 ,ug./ml. Minimal concentrations of the order of 200 ug./ml. have been generally observed during the hour preceding each administration following the first. From the data reported in Fig. 4 it can be seen that, at 32 hours after injection, concentrations of about 8 ,ug./ml. were still present in the bile. In order to evaluate whether any modification had 18-9 ± 3-2 17-3 ± 3-6 13-0 ± 3 5
RESULTS

EXCRETION OF RIFAMIDE Biliary concentrations of rifamide are presented in
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(136-7 ± 28-9) 50-7 ± 20-4 49-2 ± 8-6 (43-0 ± 7-0) 8-5 ± 1-8 12-3 ± 4-2 12-2 ± 4-0 10-9 ± 3-6 14-3 ± 4-1 11-2 ± 3-0 (18-9 ± 5-4) 12-3 ± 4-7 15-0 ± 2-8 (63-7 ± 11-7) 26-9 ± 3-6 Rifamide 12-8 ± 1-2 4-2 ± 1-1 3-4 ± 1-2 4-1 ± 1-3 (6-9 3 0) Control 14-9 ± 4-3 9-9 ± 3-7 4-3 ± 1-3 (8-7 ± 2-4) was studied only for six hours, are reported in Table V . From these data it can be seen that the differences between the two periods are statistically significant. The excretion per hour of cholesterol is also decreased during the treatment with rifamide.
CONCENTRATION OF RIFAMIDE IN THE GALL BLADDER
WALL The data are reported in Table V The values for concentrations of rifamide in the gall bladder wall suggest the possibility that the drug diffuses in the wall both from blood and from bile.
In our cases, the cystic duct was always patent but the gall bladders contained a great number of stones. This fact resulted in a remarkable decrease of the space available for the bile entering the gall bladder from the liver and containing high concentrations of rifamide. For this reason, it may be speculated that the contribution of the rifamide contained in the bile to the concentrations in the gall bladder wall was inferior to what could be expected on the basis of the very high biliary concentrations when no stones are present in the gall bladder. However, the levels 
